CDK5通过上调TAZ激活Hippo信号通路介导肺癌放疗抵抗
该研究探讨CDK5在非小细胞肺癌放疗抵抗中的作用及机制。方法包括中性彗星实验、γ-H2AX和Rad51焦点染色、克隆存活实验和异种移植瘤模型,在A549和H1299细胞中敲低CDK5。结果表明CDK5缺失在体内外损害肺癌进展和放疗抵抗,机制上TAZ是CDK5的关键下游效应分子,CDK5通过TAZ激活Hippo信号通路,提示CDK5可能是有前景的放疗增敏靶点。
要点
- CDK5缺失在体内外损害肺癌进展和放疗抵抗。
- TAZ是CDK5的关键下游效应分子,CDK5通过TAZ激活Hippo信号通路。
- CDK5可能是肺癌放疗增敏的潜在靶点。
核心结论
- CDK5通过上调TAZ激活Hippo信号通路参与肺癌肿瘤发生和放疗抵抗,提示CDK5可能是肺癌放疗增敏的有前景靶点。
研究设计与样本
- 研究采用中性彗星实验和γ-H2AX及Rad51焦点染色检测DNA损伤应答与修复,用克隆存活实验和异种移植瘤模型评估CDK5在肺癌放疗抵抗中的生物学功能,用siRNA和shRNA在A549和H1299细胞中敲低CDK5,并通过RNA-seq和qRT-PCR检测基因表达。
主要发现
- CDK5缺失在体外和体内损害肺癌进展和放疗抵抗。
- TAZ是Hippo通路的组分,被鉴定为CDK5的关键下游效应分子。
- CDK5缺失下调TAZ表达并减弱Hippo信号通路激活。
- TAZ是介导CDK5在肺癌中生物学功能的主要效应分子。
临床怎么用
- CDK5可能作为肺癌放疗增敏的潜在靶点,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor resistance to radiation therapy is a therapeutic challenge in the treatment of patients with non-small cell lung cancer. Cyclin-dependent kinase 5 (CDK5) has been proposed to participate in cell proliferation, migration and invasion, drug resistance, and immune evasion. However, the functions and regulatory mechanisms of CDK5 in lung cancer radioresistance have not been investigated. METHODS AND MATERIALS: DNA damage response and repair were measured by neutral comet assay and γ-H2AX and Rad51 foci staining. The biological functions of CDK5 in lung cancer radioresistance were investigated with clonogenic survival assays and xenograft tumor models. Small interfering RNAs and short hairpin RNAs were used to knock down CDK5 in A549 and H1299 cells. The effects of CDK5 depletion on the tumorigenic behaviors of lung cancer cells were evaluated in vitro and in vivo. Gene expression was examined by RNA-seq and quantitative real-time polymerase chain reaction. RESULTS: We report that CDK5 depletion impairs lung cancer progression and radioresistance in vitro and in vivo. Mechanistically, we identify TAZ, a component of the Hippo pathway, as a critical downstream effector of CDK5. Loss of CDK5 downregulates TAZ expression and attenuates Hippo signaling activation. Importantly, we provide evidence that TAZ is the major effector mediating the biological functions of CDK5 in lung cancer. CONCLUSIONS: These results illustrate that CDK5 activates Hippo signaling via TAZ to participate in tumorigenesis and radioresistance, suggesting that CDK5 may be a promising radiosensitization target for the treatment of lung cancer.
引用
- Zeng Y, Liu Q, Wang Y, et al. CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32407930. doi:10.1016/j.ijrobp.2020.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。